PlatformPlatform overviewCOA reviewSupplier document collectionSupplier follow-up (Vera)Supplier qualificationRelease workflowsMock inspections (Cato)Chain of custodyPatient traceabilityUnit-level traceabilityPartner RecordAPIPricing
SolutionsCompounding pharmacies503B outsourcing facilitiesClinicsMed spasTelehealth platformsConsultantsSolutions overview
ResourcesMethodologyOrder-level COA traceabilitySupplier packet diligenceResource libraryPublic toolsIntelligenceTrust Center
CompanyAbout VerituraWhy independentPartnersFor counselContact
Sign inGet a demo

Study: 114 FDA warning letters to telehealth companies. Counted by claim type.

Every letter the FDA's index returns for telehealth, read in full and counted by the sentence the FDA wrote and the wording it quoted. Last reviewed November 18, 2026.

114 letters, four roundsSeptember 2025 to October 2026

Issued

  • September 9, 202558 letters
  • February 20, 202630 letters
  • June 8, 202625 letters
  • October 30, 20261 letter

The FDA's sentences

  • The same as an approved product58, all in 2025
  • The label names the company52, all in 2026
  • Approved or otherwise evaluated42, all in 2026

Counted from the letters as published on November 18, 2026. No company is named.

What the FDA's Warning Letters to Telehealth Companies Cite: A Count by Claim Type

Abstract. Between September 9, 2025 and October 30, 2026 the FDA issued 114 warning letters whose subject line carries the word "Telehealth". All of them concern the marketing of compounded drugs, and each one quotes the wording it objects to. This study reads all 114 and counts two things. The first is the FDA's own reasoning, which is written in a small number of sentences that repeat from letter to letter. The second is the wording the letters quote from the companies. The letters went out in four rounds, and the reasoning changed from one round to the next. Every letter of September 2025 says the company's claims imply that its product is the same as an approved one. No letter of 2026 says that. Fifty-two of the 56 letters issued in 2026 say that a label pictured on the website presents the company as the compounder. No company is named in this study.

Veritura. Reviewed November 18, 2026. Written for the founder, counsel or marketing lead at a telehealth company that offers compounded drugs.

1. The population

The FDA publishes its warning letters in a searchable index. On November 18, 2026 a search of that index for the word "telehealth" returned 115 entries. One is a 2021 letter on an unrelated subject whose subject line does not contain the word. The remaining 114 are the population of this study.

They were issued on four dates.

RoundIssuedPosted by the FDALettersSubject line
1September 9, 2025September 16, 202558"Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth)"
2February 20, 2026March 3 and 5, 202630"False & Misleading Claims/Misbranded (Telehealth)"
3June 8, 2026June 16, 202625"False & Misleading Claims/Misbranded (Telehealth)"
4October 30, 2026November 3, 20261"False & Misleading Claims/Misbranded (Telehealth)"

Two companies received more than one letter. One received a letter in each of the first three rounds, and one received two in the first round. Each letter is counted once.

Every letter rests on the same two provisions. In the letters' words, "a drug is misbranded if its labeling is false or misleading in any particular" under section 502(a) of the Federal Food, Drug, and Cosmetic Act, and under section 502(bb) "a compounded drug is misbranded if its advertising or promotion is false or misleading in any particular."

2. Method

We saved the text of each letter from the FDA's website and counted in two ways.

The FDA's reasoning is counted by exact sentence. The agency writes these letters from a template, and a given objection is stated in the same words each time, with a singular variant where a letter cites one claim. A letter is counted for a sentence when the sentence appears in it. These counts can be reproduced by anyone with the letters and a text search.

The companies' wording is counted from the passages each letter places in quotation marks. A pattern was written for each type, run across all 114 letters, and checked by reading 22 letters in full, drawn from every round. Where the pattern and the reading disagreed, the pattern was corrected and run again. These counts depend on the definitions given under table 2, and a reader who draws the lines differently will get somewhat different numbers.

3. Results

Table 1. The FDA's own sentences

What the FDA wroteSep 2025 (58)Feb 2026 (30)Jun 2026 (25)Oct 2026 (1)All (114)
"Compounded drug products are not FDA-approved."5824171100
"Your claims imply that your products are the same as an FDA-approved product when they are not."5800058
The pictured label identifies the company, "suggesting [it] is the compounder of those drugs when in fact it is not."03021152
The claims imply or represent that the products "have been FDA-approved or otherwise evaluated for safety and effectiveness when they have not."02417142
Compounding facilities "are not 'FDA-approved' or 'FDA-licensed' entities."0011011
A description of the product's origin "creates a misleading impression regarding the product's true origin"00011

The second row includes 12 letters that use the singular, "Your claim implies". The fourth row combines the wording of February ("Your claims imply that your products have been FDA-approved") with the wording of June and October ("Your claims represent that the compounded drug products you offer have been FDA-approved").

Table 2. The wording the letters quote

Quoted wordingSep 2025Feb 2026Jun 2026Oct 2026All
The word "same", most often "same active ingredient"311611058
The phrase "same active ingredient" or "same active ingredients"28128048
"Generic" beside the name of a brand910010
The company's own product or ingredient described as FDA-approved, or in similar words1343121
The pharmacy described as FDA-approved, or in similar words1011012
"Clinically proven"1262020

The fourth row excludes wording that calls a brand-name drug approved for the purpose of comparison. The fifth row includes one September letter that quotes "FDA-monitored"; the other eleven quote "FDA-approved" or "FDA-licensed". Where the definition of the last row is widened to any quoted reference to clinical study or to a percentage result, the count is 26.

4. The reasoning changed from round to round

In September 2025 the objection is sameness. All 58 letters carry the sentence in the second row of table 1, and none carries any of the sentences below it. Only 31 of the 58 quote wording that contains the word "same". The others quote a brand name set beside the compounded product, the word "generic", or a product described as a brand's "compounded version". The FDA read each of these as the same implication.

In February 2026 the sameness sentence is gone and two others take its place. All 30 letters say that a label pictured on the website presents the company as the compounder. All 30 of them, and all 21 June letters that make the point, add a footnote quoting 21 CFR 201.1(h)(2): "The appearance on a drug product label of a person's name without qualification is a representation that the named person is the sole manufacturer of the product." The October letter makes the same point without the citation. Twenty-four of the 30 also say that the company's claims imply its products have been approved or otherwise evaluated.

In June 2026 a third objection appears. Eleven of the 25 letters quote a description of the pharmacy as "FDA-approved" or "FDA-licensed" and answer it directly: "The FD&C Act does not establish an 'FDA-approved' or 'FDA-licensed' designation for pharmacies or outsourcing facilities."

The single letter of October 2026 adds two things. It objects to a description of the product's origin, on the ground that "based on FDA's records, the active pharmaceutical ingredient in the product was not made in the U.S." It also addresses disclaimers. Statements on the company's website and in its video that a compounded preparation is not approved, the letter says, "do not cure the misleading overall impression created by these claims." That letter is also the first in the population to cite posts on a social media platform.

5. What the letters ask for

Every letter sets a deadline of fifteen days for a written response. The 89 letters of September, February and October say "fifteen (15) working days", and the 25 of June say "fifteen (15) business days".

The September letters ask for the steps taken and do not say what a response should contain. All 56 letters of 2026 do. In the February wording, the steps they list begin with "Identifying the entities that produce the compounded products offered on your website" and "Providing a representative sample of labeling for such products". The June and October letters say "compounded drug products". A company that receives one of these letters is therefore asked for two records that sit with its pharmacy as much as with its marketing team.

6. The drugs

Semaglutide is named in 109 letters and tirzepatide in 87. Six letters of September 2025 name retatrutide. Sildenafil and tadalafil are each named in four September letters, and liraglutide in three letters of 2026.

7. What the count does not show

A warning letter is an allegation. The recipient may respond, and this study does not follow what happened afterward.

The letters cite examples. Each says in some form that its list is not exhaustive, so a type of claim that goes uncounted here has not been found acceptable.

A count of sentences cannot show what the pictured labels looked like. The letters describe the labels, and we have not seen them.

The population is the letters the FDA's index returns for one search term. A letter on the same subject whose subject line and text do not contain the word would be missed. An earlier internal count of this population found 113 letters. This recount finds 114, with 58 in the first round, and we cannot say which letter the earlier count omitted.

8. Limits of this study

Counts were made on November 18, 2026 from the letters as published on the FDA's website on that date. Quotations were checked against the published letters. Table 1 is a count of exact sentences. Table 2 is a count by pattern, checked by hand on 22 of 114 letters. This study reports what the letters cite. It does not advise on what a company may say.

Sources

  • FDA, Warning Letters index, searched for "telehealth" on November 18, 2026: 114 letters with "(Telehealth)" in the subject line, issued September 9, 2025, February 20, 2026, June 8, 2026 and October 30, 2026.
  • Federal Food, Drug, and Cosmetic Act, sections 502(a) and 502(bb), 21 U.S.C. 352(a) and 352(bb), as characterized in the letters.
  • 21 CFR 201.1(h)(2), as quoted in the letters of February and June 2026.

A company that wants its own pages read against the wording these letters cite can start with a free claims review.

We review documents. We do not test material.

Your website, read against these letters. Free.

Send us your company’s web address. Within one business day you get one document: each sentence that matches a claim type the FDA has cited, with the FDA’s own reason and a corrected sentence beside it.